Elaine J Heron bought $16k of VXRT
director at Vaxart, Inc.. 40,000 shares at an average of $0.40, traded Nov 17, 2025, filed Nov 21, 2025.
Score components
- +15RoleDirector
- 0Trade size$16k at market
- +10Relative to holdingsHoldings up 71%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-035952, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | POpen-market purchase Common Stock | +23,217 | $0.39 | $9,124 | 79,783 | Nov 21, 2025 |
| Nov 17, 2025 | POpen-market purchase Common Stock | +16,783 | $0.41 | $6,797 | 96,566 | Nov 21, 2025 |
Related signals
Other insiders at Vaxart, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | Vaxart, Inc. | W. Mark Watson director | $8,185 20,000 shares | +19% | |
| 40Moderate | Vaxart, Inc. | Kevin Finney director | $62k 166,668 shares | +437% | |
| 26Weak | Vaxart, Inc. | W. Mark Watson director | $4,050 10,000 shares | +11% | |
| 40Moderate | VXRTbuy Vaxart, Inc. | Steven Lo President, Chief Exec Officer | $49k 100,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.